Physician profile
Albert M Ong
NPI 1053365767
$77,498.03
in general payments reported to CMS, 2019-2025
57 companies · $1,011 in 2025
The $1,011 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,582 · 2020: $9,203 · 2021: $33K · 2022: $25K · 2023: $1,452 · 2024: $1,844 · 2025: $1,011.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,557 · Consulting Fee: $750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,556.93 |
| Consulting Fee | $750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $67,776.95 | 2019-2024 | 1788 |
| Astellas Pharma US INC | $1,035.68 | 2019-2025 | Xtandi, Myrbetriq, Veozah |
| Myriad Genetic Laboratories, INC. | $863.60 | 2020-2025 | Myrisk, Prolaris |
| Endo Pharmaceuticals INC. | $750.95 | 2019-2024 | Xiaflex, Aveed |
| Coloplast Corp | $672.23 | 2019-2025 | |
| Janssen Biotech, INC. | $634.49 | 2019-2025 | Erleada, Akeega |
| Bayer Healthcare Pharmaceuticals INC. | $416.81 | 2020-2025 | |
| Boston Scientific Corporation | $389.21 | 2019-2025 | Lithovue |
| Pfizer INC. | $314.99 | 2019-2025 | |
| Tolmar Pharmaceuticals, INC. | $306.94 | 2020-2022 | |
| Ferring Pharmaceuticals INC. | $290.26 | 2019-2025 | Adstiladrin |
| Dendreon Pharmaceuticals LLC | $282.80 | 2019-2025 | Provenge |
| Sumitomo Pharma America, INC. | $252.37 | 2023-2025 | Orgovyx, Gemtesa |
| Olympus America INC. | $243.82 | 2019-2023 | Itind System |
| Acerus Pharmaceuticals Corporation | $231.34 | 2020-2022 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Ong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.